Genetic testing plays a critical role in diagnosing hereditary conditions, guiding treatment decisions, and predicting disease risks. As technology advances, medical billing and coding must keep pace. The 2026 CPT code updates introduce several new genetic testing codes, impacting medical practices, laboratories, and insurance reimbursement.
If you handle medical coding, billing, or revenue cycle management for pathology medical billing, understanding these updates is crucial for accurate claims submission and compliance. The correct CPT code for genetic testing depends on the analyte tested and the method used. There’s no single procedure code for genetic testing, so this guide breaks the codes down by category, from Tier 1 analyte codes to full genomic panels.
Stop Losing Money on Genetic Tests!
Let MedCare MSO handle your CPT coding so you get every dollar you deserve, fast and accurate.
Overview of 2026 CPT Code Changes for Genetic Testing
Current Procedural Terminology (CPT) codes are used in medical billing to report diagnostic procedures, including genetic tests. The genetic testing CPT codes are divided into three main categories:
- Tier 1 Molecular Pathology Codes – Standardized tests for commonly analyzed genes, such as BRCA1/BRCA2.
- Tier 2 Molecular Pathology CPT Codes – Used for less common genetic markers and panel-based tests.
- Proprietary Laboratory Analyses (PLA) Codes – Lab-specific genetic tests used by individual providers.
- Genomic Sequencing Procedure (GSP) Codes – Codes assigned to next-generation sequencing (NGS) and panel-based genomic testing.
Each year, the CPT code set is updated to reflect advancements in medical services. The 2026 CPT code update includes new codes for genetic and molecular testing, particularly in:
- Proprietary Laboratory Analyses (PLA) Codes
- Molecular Diagnostics
- Hereditary Testing
These updates help healthcare providers bill correctly for genetic testing services, ensuring faster reimbursements and fewer claim denials.
Scenario:
Handling Genetic Test Claim Denials A clinic submits a genetic test claim using an outdated CPT code, leading to a denial from the payer. The billing team reviews the updated 2026 CPT codes, resubmits the claim with proper documentation, and successfully secures reimbursement. Lesson: Always verify new CPT codes before submitting claims to avoid revenue loss.
Scenario:
Handling Genetic Test Claim Denials
A clinic submits a genetic test claim using an outdated CPT code, leading to a denial from the payer. The billing team reviews the updated 2026 CPT codes, resubmits the claim with proper documentation, and successfully secures reimbursement. Lesson: Always verify new CPT codes before submitting claims to avoid revenue loss.
2026 Optimized CPT Coding Guide for Molecular Pathology
The American Medical Association (AMA) has introduced 420 updates to the CPT code set, including 270 new codes, 112 deletions, and 38 revisions. Notably, 37% of the new codes pertain to proprietary laboratory analyses, primarily focusing on novel genetic testing.
Tier 1 Analyte Codes
| Code | Description |
|---|---|
| 81161 | DMD gene analysis; deletion/duplication (Duchenne/Becker muscular dystrophy) |
| 81162 | BRCA1/BRCA2 gene analysis; full sequence + duplication/deletion |
| 81163 | BRCA1/BRCA2 gene analysis; full sequence |
| 81170 | ABL1 gene analysis, kinase domain variants (imatinib resistance) |
| 81200 | ASPA gene analysis, common variants (Canavan disease) |
| 81201 | APC gene analysis; full gene sequence (familial adenomatous polyposis) |
| 81202 | APC gene analysis; known familial variants |
| 81203 | APC gene analysis; duplication/deletion variants |
| 81205 | BCKDHB gene analysis, common variants (maple syrup urine disease) |
| 81206 | BCR/ABL1 gene analysis; major breakpoint (CML) |
| 81207 | BCR/ABL1 gene analysis; minor breakpoint |
| 81208 | BCR/ABL1 gene analysis; other breakpoint |
| 81210 | BRAF gene analysis, V600 variants (colon cancer, melanoma) |
| 81225 | CYP2C19 gene analysis, common variants (drug metabolism) |
| 81226 | CYP2D6 gene analysis, common variants (drug metabolism) |
| 81227 | CYP2C9 gene analysis, common variants (drug metabolism) |
| 81235 | EGFR gene analysis, common variants (non-small cell lung cancer) |
| 81240 | F2 (prothrombin) gene analysis, 20210G>A variant |
| 81241 | F5 (Factor V Leiden) gene analysis, Leiden variant |
| 81243 | FMR1 gene analysis; detect abnormal alleles (fragile X) |
| 81245 | FLT3 gene analysis; internal tandem duplication (ITD) variants |
| 81256 | HFE gene analysis, common variants (hereditary hemochromatosis) |
| 81257 | HBA1/HBA2 gene analysis; common deletions or variant (alpha thalassemia) |
| 81270 | JAK2 gene analysis, V617F variant (myeloproliferative disorder) |
| 81275 | KRAS gene analysis; variants in exon 2 (codons 12, 13) |
| 81288 | MLH1 promoter methylation analysis (Lynch syndrome) |
| 81291 | MTHFR gene analysis, common variants (677T, 1298C) |
| 81292 | MLH1 gene analysis; full sequence (Lynch syndrome) |
| 81295 | MSH2 gene analysis; full sequence |
| 81298 | MSH6 gene analysis; full sequence |
| 81310 | NPM1 gene analysis, exon 12 variants (acute myeloid leukemia) |
| 81311 | NRAS gene analysis, variants in exons 2, 3 (colorectal carcinoma) |
| 81321 | PTEN gene analysis; full sequence (Cowden syndrome) |
| 81329 | SMN1 gene analysis; dosage/deletion (spinal muscular atrophy) |
| 81345 | TERT gene analysis, targeted sequence (promoter region) |
| 81351 | TP53 gene analysis; full gene sequence (Li-Fraumeni syndrome) |
| 81361 | HBB gene analysis; common variant(s) (sickle cell, beta thalassemia) |
Tier 2 Molecular Pathology CPT Codes by Complexity Level
| Code | Description |
|---|---|
| 81400 | Molecular pathology procedure, Level 1 |
| 81401 | Molecular pathology procedure, Level 2 |
| 81402 | Molecular pathology procedure, Level 3 |
| 81403 | Molecular pathology procedure, Level 4 |
| 81404 | Molecular pathology procedure, Level 5 |
| 81405 | Molecular pathology procedure, Level 6 |
| 81406 | Molecular pathology procedure, Level 7 |
| 81407 | Molecular pathology procedure, Level 8 |
| 81408 | Molecular pathology procedure, Level 9 |
Genomic Sequencing Procedures (Panels, Exome, Genome)
| Code | Description |
|---|---|
| 81415 | Exome; sequence analysis |
| 81425 | Genome; sequence analysis |
| 81432 | Hereditary breast cancer panel; sequencing, ≥10 genes |
| 81435 | Hereditary colon cancer panel; sequencing, ≥10 genes |
| 81443 | Severe inherited conditions carrier panel; sequencing, ≥15 genes |
| 81479 | Unlisted molecular pathology procedure |
Related MAAA, PLA & HCPCS Codes for Genetic Testing
| Code | Description |
|---|---|
| 81542 | Oncology (prostate), mRNA expression profile, metastasis risk score (Decipher), MAAA |
| 81599 | Unlisted multianalyte assay with algorithmic analysis (MAAA) |
| 0345U | Psychiatry genomic panel, 15 genes incl. CYP2D6 del/dup (GeneSight), PLA |
| 0449U | Carrier screen for severe inherited conditions, 5 genes (CFTR, SMN1, HBB, HBA1, HBA2; UNITY), PLA. Note: some payers ended 0449U coverage as of Jan 1, 2026, verify payer policy. |
| G0452 | Molecular pathology procedure; physician interpretation and report (HCPCS) |
Billing Guidelines for Medicare Coverage and Molecular Pathology Procedures
The 2026 CPT coding updates include modifications in molecular testing, sequencing, and risk assessment. Below is a breakdown:
Medicare Billing for Non-Covered Services
It is improper to bill Medicare for non-covered services as if they are covered. When submitting claims for services that are not eligible for coverage, ensure the correct modifier is applied.
Gene-Specific Code Selection
Code selection depends on the specific gene (s) being analyzed. Codes for gene variant testing use common variant names. While the listed variants are typically included in the test, this list is not exhaustive. Any additional variants of the same gene included in the analysis are part of the procedure and should not be reported separately.
Full gene sequencing should not be reported using variant-specific codes unless the CPT code explicitly includes “full gene sequence” in its description.
Tier 1 and Tier 2 Molecular Pathology Codes
- Tier 1 codes apply to tests for a specific gene or Human Leukocyte Antigen (HLA) locus.
- Tier 2 codes (81400-81408) cover molecular pathology procedures not listed in Tier 1 and typically represent lower-volume or rare disease testing. These codes should be used only when necessary and as specified in coding and billing policies.
If a claim includes the following Tier 2 codes, additional details must be provided in the claim narrative to specify the gene(s) analyzed. Otherwise, the claim may be rejected:
- 81400
- 81401
- 81402
- 81403
- 81404
- 81405
- 81406
- 81407
- 81408
- 81479 (Unlisted Molecular Pathology)
Reporting Unlisted Molecular Pathology Code (81479)
Providers must use the procedure code that best describes the performed service. If no Tier 1 or Tier 2 code appropriately represents the analyte tested, the unlisted molecular pathology code (81479) should be used.
The CPT code 81479 description is an unlisted molecular pathology procedure. This is why it’s often applied to newer next-generation sequencing panels and lab-developed tests that don’t yet have a dedicated code. Also, CPT code 81479 reports a genetic test, just one without a defined code of its own.
When billing 81479, the gene being tested must be specified in:
- Block 80 (Part A for UB-04 claims)
- Box 19 (Part B for paper claims)
- Electronic equivalent fields for digital claims
Lastly, do know that no CPT modifier or ICD-10 diagnosis code is used when billing 81479. Failure to include this information will result in claims being returned or denied.
Documentation for Multiple Procedure Codes
If multiple procedure codes are submitted on a claim (whether standard or unlisted), documentation must clearly support each code. If the documentation does not correspond with the billed codes, the services may be denied under Title XVIII of the Social Security Act, Section 1833.
Testing for Multiple Genes & Next-Generation Sequencing (NGS)
Testing a panel of genes differs from testing individual genes separately. Claims must be medically justified:
- If billing for a panel, medical records must support its necessity.
- If billing for individual genes, each must be justified as necessary in the patient’s record.
Genes tested on the same date of service are categorized as:
- Parallel Testing: When multiple genes are analyzed at the same time for the same indication without one result influencing another.
- Serial Testing: When gene analysis is done in sequence, with later tests depending on earlier results.
If NGS technology is used and multiple genes are tested in parallel, they are considered part of a single panel, in alignment with the NCCI Manual (Chapter 10, Section F, Number 8). If genes are tested in a serial manner, claims should be submitted individually for each gene. The treating clinician’s order must reflect whether they requested a panel or individual genes, and records should support the medical necessity of the service billed.
Medicare policy does not allow separate payment for different testing methods applied to the same analyte.
Billing multiple distinct genetic tests for a single patient on the same date is generally not expected. In rare cases where more than one test is medically necessary, providers must confirm each as a separate procedural service using modifier -59.
Modifier -59: Distinct Procedural Service
Modifier -59 is used to indicate that a procedure is independent from others performed on the same day, applying to radiology, surgical, or medical services when appropriate.
Billing rules for Modifier -59:
- The first reported code is billed without a modifier.
- Additional codes are billed on separate lines with the modifier.
- Documentation must support a different session, procedure, site, system, incision, lesion, or injury from other services performed on the same day.
If another, more specific modifier is available, it should be used instead of -59. Using this modifier signifies that a service is distinct rather than part of a panel and may trigger a request for medical records. Frequent use of modifier -59 may lead to medical review.
Genomic Sequencing Profiles (GSP)
When a genomic sequencing test includes genes listed under multiple code descriptors, the most specific code for the primary disorder should be reported. Submitting multiple codes for the same gene will result in claim rejection or denial.
Multianalyte Assays with Algorithmic Analyses (MAAAs) & Proprietary Laboratory Analyses (PLAs)
If a valid PLA code exists, it must be used instead of a Tier 1 or Tier 2 code. Submitting both a PLA and a Tier 1/Tier 2 code is considered incorrect coding and may result in claim denial.
MAAA component procedures should not be billed separately. Claims that report additional codes for MAAA inputs will be denied.
- PLA and MAAA codes are listed in Appendix O of the CPT Manual.
- If no specific code exists, the unlisted MAAA procedure code (81599) should be used.
- When billing 81599, a brief (under 80 characters) description of the analysis must be included in:
- Block 80 (Part A UB-04 claims)
- Box 19 (Part B paper claims)
- The electronic equivalent field for digital claims
Claims missing this information will be returned or denied. Medical records may also be requested to verify the test’s validity and necessity.
98.5%
Clean Claims
Optimize Genetic Testing Reimbursement
Accurate implementation of new CPT codes increases payments, minimizes errors, and strengthens your cash flow.
Book Demo Now35%
Reduction in A/R
Date of Service (DOS)
For clinical laboratory tests and pathology services, the DOS is typically the date the specimen was collected. If collection spans two calendar days, the DOS is the date collection ended. Exceptions to DOS policies exist, as outlined in CMS IOM Publication 100-04, Chapter 16, Section 40.8.
Documentation Requirements
All medical records must be:
- Legible and include patient identification details (name, DOS, etc.)
- Signed by the responsible physician or non-physician practitioner (NPP)
- Supportive of the reported ICD-10-CM and CPT/HCPCS codes
Per CFR Section 410.32, the medical record must demonstrate that testing influences treatment and is necessary for managing the patient’s condition.
Ordering physician/NPP documentation must include:
- Relevant history, physical exam findings, and diagnostic rationale
- Evidence of at least two E/M visits within the last six months
- Test orders that clearly specify the requested analyses
Performing laboratories must maintain records including:
- Accreditation status
- Test requisition forms
- Procedure records
- Quality control documentation
Failure to provide adequate documentation may result in claim denials or requests for additional records.
The Bottom Line
The 2026 CPT code updates for genetic testing introduce new billing opportunities and challenges for healthcare providers and laboratories. Keeping up with molecular pathology, genomic sequencing, and proprietary test codes is crucial for ensuring accurate reimbursement. Understanding payer policies, compliance requirements, and billing best practices will help streamline claims and prevent revenue loss. For a smooth transition, it’s recommended to consult coding experts and medical billing professionals who specialize in genetic testing reimbursement.
Frequently Asked Questions
How many genes does CPT code 81408 test for?
CPT code 81408 pertains to molecular pathology procedures involving the analysis of specific genes associated with certain conditions. The exact number of genes tested under this code can vary, as it includes tests for rare genetic disorders. For precise information, it’s essential to consult the latest CPT code descriptions or relevant medical billing resources.
What do molecular pathology procedure level numbers indicate?
Molecular pathology procedure codes are categorized into different tiers to reflect the complexity and resources required for the tests:
- Tier 1 Codes (e.g., 81200-81383): These codes represent well-established tests for common genetic variants.
- Tier 2 Codes (e.g., 81400-81408): These codes are divided into levels based on the technical and interpretive effort needed, with higher levels indicating more complex analyses.
Each level within Tier 2 corresponds to specific procedures and the associated complexity involved in the testing process.
What is CPT code 81479?
CPT code 81479 is designated for “Unlisted molecular pathology procedures.” It is used when a molecular pathology test doesn’t have a specific CPT code assigned. This code ensures that unique or less common genetic tests are appropriately billed, even in the absence of a designated code.
What is the CPT code for GeneSight testing?
GeneSight Psychotropic testing is represented by CPT code 0345U. This proprietary laboratory analysis evaluates how a patient’s genetic makeup may affect their response to certain psychotropic medications, analyzing multiple genes to guide treatment decisions.
What are the CPT codes for genetic testing?
Genetic testing encompasses a range of CPT codes, each corresponding to specific tests:
- 81200-81383: Molecular pathology procedures for specific gene analyses.
- 81400-81408: Tier 2 molecular pathology procedures, categorized by complexity.
- 81410-81471: Genomic sequencing procedures and other molecular multianalyte assays.
- 81479: Unlisted molecular pathology procedures.
These codes facilitate accurate billing and documentation of various genetic tests.
What are pathology CPT codes?
Pathology CPT codes range from 80047 to 89398 and cover a broad spectrum of laboratory procedures:
- 80047-80076: Organ or disease-oriented panels
- 80150-80299: Therapeutic drug assays
- 81200-81479: Molecular pathology procedures, including genetic testing
- 88300-88399: Surgical pathology
- 89250-89398: Reproductive medicine and cytogenetics
These codes are essential for billing pathology and laboratory tests, ensuring accurate reimbursement.
What is genotype testing, and what CPT codes are used for it?
Genotype testing determines an individual’s genetic sequence variations, helping assess risks for hereditary diseases and medication responses. Common CPT codes for genotype testing include:
- 81225-81227: CYP2C19, CYP2D6, and other pharmacogenetic testing
- 81291: JAK2 gene testing (used in hematologic disorders)
- 81479: Used for unlisted genetic tests when no specific CPT code applies
Pro Tip:
Before billing genotype tests, verify if the payer requires prior authorization, as many insurers have strict coverage policies for genetic testing.
What is the CMS 14 day rule?
The CMS 14-Day Rule, also known as the Date of Service (DOS) Policy, is a regulation established by the Centers for Medicare and Medicaid Services (CMS) to ensure timely submission of claims for clinical diagnostic laboratory tests.
According to this rule, Medicare requires that claims for lab services be submitted within 14 calendar days from the date of service (the date the specimen was collected). If the claim is not filed within this time frame, it may be rejected or denied.
